Capecitabine Market Poised for Steady Growth Driven by Rising Cancer Rates and Expanding Applications

The global capecitabine market is expected to witness continued growth in the coming years, fueled by a rise in cancer diagnoses, increasing adoption in combination therapies, and the development of new formulations. According to a report by Reports and Data, the capecitabine market size was valued at USD 408.2 million in 2022 and is projected to reach USD 652.9 million by 2032, growing at a CAGR of 4.9%.
Claim Your FREE Sample Copy with Table of content@ https://www.reportsanddata.com/download-free-sample/261

Market Overview

Capecitabine is an oral chemotherapy medication used to treat various types of cancer, including colorectal cancer, breast cancer, and stomach cancer. It works by blocking the growth of cancer cells. The capecitabine market encompasses various segments, including dosage forms (500 mg and 150 mg tablets), applications (breast cancer, colorectal cancer, stomach cancer), and geographical regions.

Key Trends Shaping the Market

Rising Cancer Incidence: The growing global burden of cancer, particularly colorectal and breast cancer, is a significant driver for the capecitabine market. As per the World Health Organization (WHO), in 2020, there were an estimated 19.3 million new cancer cases reported worldwide.

Expanding Application Scope: The FDA's approval of updated labeling for capecitabine tablets in December 2022, including new indications and dosing regimens, is expected to broaden its application base and drive market growth.

Focus on Combination Therapies: The effectiveness of capecitabine in combination with other chemotherapeutic agents is leading to increased adoption in multi-drug regimens for various cancers.

Market Drivers and Restraints

Growing Geriatric Population: The aging population is more susceptible to cancer, creating a larger potential patient pool for capecitabine treatment.

Technological Advancements: The development of novel drug delivery systems, such as dispersible tablets for faster absorption, can enhance patient convenience and market demand.

Stringent Regulatory Landscape: Stringent regulatory requirements for generic drug approval can pose challenges for market entry, impacting the growth of generic capecitabine.

Side Effect Profile: Capecitabine treatment can be associated with side effects like hand-foot syndrome, diarrhea, and fatigue, which may deter some patients.

Growth Opportunities

Emerging Markets: Increasing healthcare spending and rising cancer awareness in developing economies present lucrative growth prospects for the capecitabine market.

Biosimilars Development: The potential development of biosimilar versions of capecitabine with lower costs could expand access and affordability in emerging markets.

Focus on Patient Compliance: The development of patient-centric care programs and adherence support initiatives can improve treatment outcomes and drive market growth.

SWOT Analysis

Strengths:

Proven efficacy in treating various cancers

Availability of generic alternatives

Convenient oral administration

Weaknesses:

Potential side effects

Limited application in certain cancer types

Stringent regulatory requirements

Opportunities:

Rising cancer burden

Growing adoption in combination therapies

Expansion into emerging markets

Threats:

Patent expirations for brand-name drugs

Competition from new cancer treatment modalities

Stringent regulations and price control measures

Browse Detailed Research report @ https://www.reportsanddata.com/report-detail/capecitabine-market

Latest Strategic Developments

In February 2021, Dr. Reddy's Laboratories launched Capecitabine Tablets, USP, which is a therapeutic generic version of Xeloda Tablets, following approval by the U. S. FDA.

In April 2020, Seattle Genetics announced U.S. FDA approval for its TUKYSA (Tucatinib) tablets indicated for breast cancer. TUKYSA, which is a tyrosine kinase inhibitor, along with Roche's capecitabine and trastuzumab, is specifically indicated for metastatic HER2-positive breast cancer.

Companies Profiled in the Report:
Cipla Inc., Genentech, Inc., F. Hoffmann-La Roche, Ranbaxy Laboratories Ltd., Teva Pharma B.V., Mylan N.V., Sandoz, Fresenius SE & Co. KGaA, Zentiva N.V., Accord Healthcare Ltd., and Dr. Reddy Laboratories Ltd. are some of the major companies operating in the global capecitabine market.

For the purpose of this report, the global capecitabine market is segmented based on indication, drug type, drug formulation, end-use, distribution channel, and region:

Indication Outlook (Revenue, USD Billion; 2018-2028)
Breast Cancer

Colorectal Cancer

Gastric Cancer

Others

Drug Type Outlook (Revenue, USD Billion; 2018-2028)
Branded

Generic

Drug Formulation Outlook (Revenue, USD Billion; 2018-2028)
Tablets

Capsules

End-use Outlook (Revenue, USD Billion; 2018-2028)
Hospitals

Specialty Clinics

Homecare

Others

Distribution Channel Outlook (Revenue, USD Billion; 2018-2028)
Hospital Pharmacies

Retail Stores

Online Pharmacies

Others

Ask For Customization: https://www.reportsanddata.com/request-customization-form/261
Region Outlook (Revenue, USD Billion; 2018-2028)
North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Italy

Spain

Benelux

Rest of Europe

Asia Pacific

China

India

Japan

Singapore

Rest of Asia Pacific

Latin America

Brazil

Rest of Latin America

Middle East and Africa

Saudi Arabia

UAE

South Africa

Rest of Middle East & Africa

Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision

This release was published on openPR.